New Delhi: The Drug Controller General of India (DCGI) has issued a notice to Glenmark Pharmaceuticals on a false claim that its antiviral drug FabiFlu has been effective on COVID-19 patients with co-morbidities.
The DCGI issued the notice following complaints from a Member of Parliament (MP) over the high price of the drugs and false claim.
The drug controller body, however, did not name the MP in its notice. Earlier in June, DCGI gave approval to Glenmark for manufacture and marketing of FabiFlu for treating mild COVID-19 patients.
Earlier, the cost of each FabiFlu tablet was Rs 103 which was later revised by the company and announced a new price for the per tablet at Rs 75.
A COVID 19 patients need to complete a course of 122 tablets.
Meanwhile, in a positive development, as many as 26 Delhi police personnel on Sunday have donated their plasma at a Plasma donation camp organised by AIIMS.
All these police personnel have been recovered from COVID-19.
"As of now convalescent plasma therapy has been approved for compassionate use with various plasma banks being set up to ensure round the clock availability. Despite the fact that India has one of the highest cure rates amongst COVID-19 patients, the plasma donations have yet to pick up," said Dr Harsh Vardhan while inaugurating the plasma bank.
Read: PM Modi speaks to CMs of several states to discuss COVID-19 situation
Meanwhile, India's COVID-19 case fatality rate on Sunday dropped to 2.49 per cent highlighting a successful clinical management plan of hospitalised cases.
India is one of the lowest fatality rates in the world. Significantly, as many as 29 states and UTs have registered case fatality rate lower than the national average.
